BRPI1012182A2 - composições e métodos para tratar isquemia e lesão de isquemia-reperfusão - Google Patents

composições e métodos para tratar isquemia e lesão de isquemia-reperfusão

Info

Publication number
BRPI1012182A2
BRPI1012182A2 BRPI1012182A BRPI1012182A BRPI1012182A2 BR PI1012182 A2 BRPI1012182 A2 BR PI1012182A2 BR PI1012182 A BRPI1012182 A BR PI1012182A BR PI1012182 A BRPI1012182 A BR PI1012182A BR PI1012182 A2 BRPI1012182 A2 BR PI1012182A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
reperfusion injury
treating ischemia
ischemia
Prior art date
Application number
BRPI1012182A
Other languages
English (en)
Inventor
Alan S Lader
Alexander B Baguisi
Ralph Casale
Reinier Beeuwkes
Steven A Kates
Original Assignee
Ischemix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ischemix Llc filed Critical Ischemix Llc
Publication of BRPI1012182A2 publication Critical patent/BRPI1012182A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
BRPI1012182A 2009-05-14 2010-05-13 composições e métodos para tratar isquemia e lesão de isquemia-reperfusão BRPI1012182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/466,170 US7928067B2 (en) 2009-05-14 2009-05-14 Compositions and methods for treating ischemia and ischemia-reperfusion injury
PCT/US2010/034701 WO2010132657A1 (en) 2009-05-14 2010-05-13 Compositions and methods for treating ischemia and ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
BRPI1012182A2 true BRPI1012182A2 (pt) 2016-04-05

Family

ID=42244916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012182A BRPI1012182A2 (pt) 2009-05-14 2010-05-13 composições e métodos para tratar isquemia e lesão de isquemia-reperfusão

Country Status (17)

Country Link
US (5) US7928067B2 (pt)
EP (1) EP2429519B1 (pt)
JP (2) JP5570590B2 (pt)
KR (1) KR101636395B1 (pt)
CN (1) CN102802622B (pt)
AU (1) AU2010249001B2 (pt)
BR (1) BRPI1012182A2 (pt)
CA (1) CA2761798C (pt)
DK (1) DK2429519T3 (pt)
ES (1) ES2470673T3 (pt)
HK (1) HK1167082A1 (pt)
IL (2) IL216349A (pt)
MX (2) MX347460B (pt)
NZ (1) NZ596364A (pt)
PL (1) PL2429519T3 (pt)
SG (1) SG176062A1 (pt)
WO (1) WO2010132657A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
WO2012067947A1 (en) 2010-11-18 2012-05-24 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
JP6466833B2 (ja) 2012-05-11 2019-02-06 ジェムバックス アンド カエル カンパニー,リミティド 抗炎症活性を有するペプチド、及びそれを含む組成物
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
JP6474786B2 (ja) * 2013-04-19 2019-02-27 ジェムバックス アンド カエル カンパニー,リミティド 虚血性損傷の治療及び予防用の組成物
CN104508485B (zh) 2013-06-07 2017-01-18 杰姆维克斯&凯尔有限公司 在癌症免疫疗法中有用的生物标记
EP3011967B1 (en) 2013-06-21 2020-06-17 Gemvax & Kael Co., Ltd. Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
ES2773296T3 (es) 2013-10-23 2020-07-10 Gemvax & Kael Co Ltd Composición para tratar y prevenir la hiperplasia prostática benigna
CN105848667B (zh) 2013-11-22 2020-05-19 珍白斯凯尔有限公司 具有血管生成抑制活性的肽和包含所述肽的组合物
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー,リミティド 前立腺癌治療用組成物
KR102373603B1 (ko) 2014-04-11 2022-03-14 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds
CN104095835A (zh) * 2014-06-20 2014-10-15 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗肝缺血/再灌注损伤药物中的应用
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー,リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN106083800A (zh) * 2016-06-13 2016-11-09 崔坤峰 氯普噻吨的药物组合物及对脑缺血再灌注损伤的保护作用
EP3522880B1 (en) * 2016-10-05 2020-12-02 Mitobridge, Inc. Methods of treating acute kidney injury
EP4282411A1 (en) * 2017-04-25 2023-11-29 Ischemix LLC Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
KR102112949B1 (ko) 2019-02-12 2020-05-19 남현규 복합 효모 발효로 불용 단백질을 가용화하여 화장품원료를 추출하는 화장품원료 제조방법

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1047991B (de) 1957-11-20 1958-12-31 Nordmark Werke Gmbh Verfahren zur Herstellung chemisch stabiler, untoxischer, steriler Injektionsloesungen von Thioctsaeure
US3875207A (en) * 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
CA1219824A (en) 1981-04-17 1987-03-31 David C. Ward Modified nucleotides and methods of preparing and using same
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
FR2653334B1 (fr) 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
IE904034A1 (en) 1989-11-09 1991-05-22 Asta Medica Ag A medicament containing r-ó-lipoic acid or s-ó-lipoic acid¹as active substance
DE4000397A1 (de) 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
AU4021393A (en) 1992-04-24 1993-11-29 Biocompatibles Limited Metal coatings
DE4235912C2 (de) 1992-10-23 2002-12-05 Viatris Gmbh Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
WO1997000889A1 (fr) * 1995-06-21 1997-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Peptides de liaison de lipoproteines de faible densite
JPH0990542A (ja) 1995-09-28 1997-04-04 Konica Corp ハロゲン化銀写真感光材料
FR2741075B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant
AU728488B2 (en) 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
JPH117099A (ja) 1997-06-13 1999-01-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6090842A (en) 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
DE19834608A1 (de) 1998-07-31 2000-02-03 Basf Ag Kristallmodifikation der Liponsäure
JP2000169371A (ja) 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
CA2352555A1 (en) 1998-11-26 2000-06-08 Pentapharm Ag Transport system conjugate
AU6462500A (en) 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
AU781678C (en) * 1999-11-18 2005-12-22 Ischemix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US8795706B2 (en) 2000-08-16 2014-08-05 Encore Health, Llc Methods of treating ocular diseases using derivatives of lipoic acid
JP2002189271A (ja) 2000-12-21 2002-07-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
DE60234164D1 (de) 2001-03-19 2009-12-10 Senju Pharma Co Neues a-liponsäurederivat und dessen verwendung
WO2002096360A2 (en) 2001-05-25 2002-12-05 Ceremedix, Inc. Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
JP4259813B2 (ja) 2001-05-29 2009-04-30 千寿製薬株式会社 α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤
DE10163836A1 (de) 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren
JP4272068B2 (ja) 2001-12-26 2009-06-03 日本曹達株式会社 自己組織化単分子膜を形成する電子受容性化合物
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
AU2003219880A1 (en) 2002-02-22 2003-09-09 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
JP2003286168A (ja) 2002-03-28 2003-10-07 Senju Pharmaceut Co Ltd α−リポイルアミノ酸を含有する皮膚外用剤
JP4376540B2 (ja) 2002-05-31 2009-12-02 アイバイツ株式会社 金属表面修飾剤および新規含硫黄化合物
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
US7202270B2 (en) 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma
WO2005077965A1 (ja) 2004-02-18 2005-08-25 Japan Science And Technology Agency 糖鎖リガンド複合体、およびそのリガンド複合体を用いたタンパク質の分析方法
JP2006022066A (ja) 2004-07-09 2006-01-26 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
WO2006101910A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
WO2006101909A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Combination therapy for treating or preventing diseases
JP2008174453A (ja) 2005-04-28 2008-07-31 Iwaki Kk 頭皮脱毛治療剤
EP1957093B1 (en) * 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
JP4951226B2 (ja) 2005-09-08 2012-06-13 立山化成株式会社 α−リポ酸アルカリ塩の製法
US20090306190A1 (en) * 2005-09-09 2009-12-10 Mary Stenzel-Poore Neuroprotectants
ES2344920T3 (es) 2006-03-28 2010-09-09 Epitech Group S.R.L. Composicion farmaceutica para el tratamiento de patologias provocadas por la respuesta general del sistema inmutario.
WO2010052310A1 (en) 2008-11-07 2010-05-14 Segix Italia S.R.L. Alpha-lipoic acid derivatives and their use in drug preparation
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
US8080674B2 (en) 2009-06-12 2011-12-20 Ampac Fine Chemicals Llc. Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt
EP2821405B1 (en) 2009-06-15 2016-04-13 Encore Health, LLC Choline esters for treating presbyopia and cataract
IT1397154B1 (it) 2010-01-04 2013-01-04 Ghelardini Composti ad efficacia sia analgesica che antiperalgesica.
WO2012067947A1 (en) 2010-11-18 2012-05-24 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
US20150329519A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations Comprising Lipoyl Compounds
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds

Also Published As

Publication number Publication date
IL237820A (en) 2016-12-29
ES2470673T3 (es) 2014-06-24
IL216349A0 (en) 2012-01-31
JP5570590B2 (ja) 2014-08-13
IL216349A (en) 2015-11-30
MX347460B (es) 2017-04-26
US8772250B2 (en) 2014-07-08
AU2010249001B2 (en) 2013-06-20
NZ596364A (en) 2013-07-26
US20140274917A1 (en) 2014-09-18
CA2761798A1 (en) 2010-11-18
US20160264622A1 (en) 2016-09-15
DK2429519T3 (da) 2014-05-19
EP2429519B1 (en) 2014-04-23
WO2010132657A1 (en) 2010-11-18
US20100292313A1 (en) 2010-11-18
CN102802622A (zh) 2012-11-28
CN102802622B (zh) 2017-03-15
SG176062A1 (en) 2011-12-29
MX2011012095A (es) 2012-03-26
CA2761798C (en) 2018-08-07
EP2429519A1 (en) 2012-03-21
PL2429519T3 (pl) 2014-09-30
US8772249B2 (en) 2014-07-08
JP2014077003A (ja) 2014-05-01
KR101636395B1 (ko) 2016-07-05
US20120135932A1 (en) 2012-05-31
JP2012526842A (ja) 2012-11-01
US7928067B2 (en) 2011-04-19
HK1167082A1 (en) 2012-11-23
US20110160294A1 (en) 2011-06-30
JP5767307B2 (ja) 2015-08-19
US9540417B2 (en) 2017-01-10
KR20120018188A (ko) 2012-02-29
AU2010249001A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
BRPI1012182A2 (pt) composições e métodos para tratar isquemia e lesão de isquemia-reperfusão
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BR112013019732A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BR112014009528A2 (pt) métodos e composições para tratar eritropoiese ineficaz
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1015250A2 (pt) métodos de estabilização e de hidrogenação para olefinas micróbio-derivadas
BRPI1008566A8 (pt) métodos e composições para o diagnóstico e tratamento de câncer
IL214664A (en) Compositions are useful for treating hair-related conditions
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BR112012002269A2 (pt) implemento para tratar superfície
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BR112012004080A2 (pt) composições farmacêuticas para tratar ibd
BRPI1013927A2 (pt) métodos e composições para o tratamento de lúpus
BRPI0920009A2 (pt) composições concentradas para tratamento de superfícies rígidas
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BR112012004699A2 (pt) Métodos e composições para lise química direta
BR112015006512A2 (pt) composição para tratar tecidos biológicos danificados
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BR112012002084A2 (pt) composições e métodos para inibir crescimento de pelo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]